1 - HAS, Commission
de la transparence.
Réévaluation des traitements hormonaux de la ménopause, 28 mai 2014.
2 - Afssaps. Mise au point juin 2008 sur le traitement hormonal de la THM-THS http://afssaps.sante.fr/htm/10/ths/thm ménopause.
3 - F. Trémollières,
C. Ribot. Le THM chez la femme ménopausée de 50 à 60 ans : quelle balance bénéfices-risques ?
CNGOF 12-18 165-172.
4 - Letombe B. Le syndrome climatérique et la qualité de vie : balance
bénéfices/risques du THM et des traitements symptomatiques. CNGOF 2010 513-542.
5 - GEMVI : www.gemvi.org
6 - Fournier A. et al. Unequal risks for breast cancer associated with different hormone replacement therapies : results from the E3N cohort study. Breast Cancer Res Treat , 2008 ; 107(1) : 103-11.
7 -Scarabin PY, and al.Differential association of oral and transdermal estrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003 Aug 9;362(9382):428-32.
8 - Fournier A., Kernaleguen C., Panjo H., Clavel-Chapelon F., Ringa V. Postmenopausal hormone therapy initiation before and after the Women's Health Initiative in two French cohorts. Menopause. 2011 Feb ; 18(2) : 219-23.
9 - Beral V; Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003 ; 362:419-427.
10 - Writing Group for the Women's Health Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women. Jama, 2002;288(3):321-333.
11 – Inca.Traitements hormonaux de la ménopause et risques de cancers. e-cancer.fr.
12 - The North American Menopause Society. The 2012 Hormone Therapy Position Statement of the North American Menopause Society. Menopause: The Journal of The North American Menopause Society, Vol. 19, No 3, pp. 257/271
13 - Canonico M., Oger E., Plu-Bureau G. et coll. Hormone therapy and venous thromboembolism among postmenopausal women. Impact of route of estrogen administration and progestogens: The ESTHER study. Circulation 2007 ;115 :840-5.
14 - Jacques E. Rossouw et al. Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause. Jama, April 4, 2007 - Vol 297, No. 13,
pp 1465-1477.
15 - Florence Tremollières et al. EMAS position statement : Managing menopausal women with a personal or family history of VTE Maturitas 2011.
16 -Antoine C. et al. Maturitas. Menopausal hormone therapy use in relation to breast cancer incidence in 11 European Countries. 2016 Feb; 84:81-8.
Etude et Pratique
Prophylaxie post-TVP : AOD pleine dose ou demi-dose ?
Recommandations
La borréliose de Lyme
Mise au point
Palpitations : orientation diagnostique
En 5 points
Obésité : suivi d’un patient sous aGLP-1